Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsKjartansdottir, Olof J
Sigurdardottir, Lara G
Olafsdottir, Elinborg J
Jonasson, Jon G
MetadataShow full item record
CitationEstrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women. 2017, 163 (2):363-373 Breast Cancer Res. Treat.
AbstractBreast cancer associated with estrogen-progestin (EP) therapy may have more favorable characteristics than cancer in never users, but results are conflicting. It is not well known either whether Body Mass Index (BMI) modifies this association. We investigated breast cancer characteristics in EP users for lean (BMI < 25 kg/m(2)) and overweight women (BMI ≥ 25 kg/m(2)).
The Icelandic Cancer Detection Clinic cohort, with information on breast cancer risk factors for 90% of Icelandic women, was linked with the population-based Icelandic Cancer Registry. A total of 781 women with invasive breast cancer diagnosed 51 years or older were matched with 7761 controls from the cohort. Conditional logistic regression was used for estimating adjusted odds ratios (OR) and 95% confidence intervals (CI) according to tumor characteristics, stratified by BMI. Polytomous logistic regression was applied in a case-only analysis for testing whether the risk associated with EP use differed according to tumor characteristics.
Ever EP users had a twofold higher risk of breast cancer compared with never users (OR 2.05, 95% CI 1.71-2.45). In lean women, EP use was significantly less likely to be associated with grade 2 or 3 tumors than grade 1 tumors, contrary to overweight women for whom risk was increased irrespective of grade. EP use in overweight women was associated with a higher risk of lobular than ductal cancer (OR 2.75, 95% CI 1.29-5.87).
Among lean EP users, tumor characteristics were more favorable than among never users. This effect was not observed for overweight women.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
RightsArchived with thanks to Breast cancer research and treatment
- Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
- Authors: Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR
- Issue date: 2003 Jun 25
- Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.
- Authors: Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R
- Issue date: 2002 Dec 15
- Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
- Authors: Rosenberg LU, Einarsdóttir K, Friman EI, Wedrén S, Dickman PW, Hall P, Magnusson C
- Issue date: 2006 Dec
- Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older.
- Authors: Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, Tryggvadottir L
- Issue date: 2014 Jun
- Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
- Authors: Glass AG, Lacey JV Jr, Carreon JD, Hoover RN
- Issue date: 2007 Aug 1